Clinical Trials

Please note:
Additional trials that are recruiting patients with various subsets of eosinophil-associated disease are listed below. Neither the search engine above nor the list on this page is to be considered exhaustive. Learn more about clinical trials, including those listed on this page, at www.clinicaltrials.gov.

 

What is a clinical trial?  Clinical trials are designed to test new medications in people. Clinical trials may involve a placebo group (inactive ‘medicine’) to see if the new medication offers an advantage over current standard treatment. Some trials are ‘open label’, in which all participants receive active medications or experimental treatment.

Clinical trial participation is an individual, and important, decision. There are many advantages to participating in clinical trials. Participants in clinical trials at a minimum receive current standard care for their disease from medical teams experienced with the disease. Clinical trials also offer the opportunity to try a new medication long before it is approved by the Food and Drug Administration. If you choose to participate in a clinical trial, you have the right to understand fully what is expected of you, what the trial will involve and the potential risks to your health. You also have the right to withdraw your consent to participate at any time.

The clinical trials listed here were verified as open and enrolling at the time the post was made, and are monitored periodically to ensure that the trial is still accepting participants. If a trial is no longer accepting patients, APFED may not be notified. If you find that registration has closed for a trial that is still listed on this page, please notify mail@apfed.org.

 

Trials That May be of Interest


Eosinophilic Esophagitis (EoE)

A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children

Ages: 4-17
Study Reference: NCT02579876
Study type: Interventional
Location: Philadelphia, PA
Learn more

A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Ages: 12 and older
Study Reference: NCT03633617
Study type: Interventional
Location: Multiple
Learn more

a4b7 Integrin in Eosinophilic Esophagitis

Ages: 18+
Study Reference: NCT02546219
Study Type: Observational
Location:  Boston, MA
Learn more

Cytosponge and Dietary Therapy in EoE

Ages:  18-70
Study Reference: NCT02599558
Study Type:  Interventional
Location:  Minnesota
Learn more

Cytosponge Protocol

Ages: 18-65
Study Reference: NCT01585103
Study type: Interventional
Location: Mayo Clinic, Rochester MN
Learn more

Esophageal Absorption in Eosinophilic Esophagitis

Ages: 18-80
Study Reference: NCT02314455
Study type: Interventional
Location: Mayo Clinic, Rochester, MI
Learn more

Phase 2 Study of Esophageal String Test in Eosinophilic Esophagitis

Ages: 7-65
Study Reference: NCT02008903
Study type: Observational
Location: Children’s Hospital Colorado (Aurora, CO); Lurie Children’s Hospital (Chicago, IL); Northwestern University (Chicago, IL)
Learn more

Eosinophilic Esophagitis Clinical Therapy Trial

Ages: 3-17
Study Reference: NCT01821898
Study type: Interventional
Location: Texas Children’s Hospital, Houston, TX
Learn more

Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids

Ages: 6-17
Study Reference: NCT02610816
Study type: Interventional
Location: Arkansas, California, Colorado, Illinois, Indiana, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
Learn more

Website for additional details

Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools

Ages: 5-80
Study Reference: NCT02453126
Study type: Observational
Location: Mayo Clinic, Rochester, MI
Learn more

FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis

Ages: ≥18 years of age
Study Reference: NCT03191864
Study Type: Interventional
Location: Multiple
Learn more  
Find out if you are eligible

Expanding the Clinical Applications of Functional Luminal Imaging (EndoFLIP) in Esophageal Stenoses

Ages: 18-80
Study Reference: NCT02354716
Study type: Observational
Location: Philadelphia, PA
Learn more

Molecular Basis of Food Allergy

Ages: 4 months-75 years
Study Reference: NCT01832324
Study type: Observational
Location: Children’s Hospital of Philadelphia
Learn more

Mucosal Impedance and Eosinophilic Esophagitis

Ages: 18-90
Study Reference: NCT01953575
Study type: Interventional
Location: Mayo Clinic, Rochester MN
Learn more

Nasal Nitric Oxide Levels in EoE

Ages: 18+
Study Reference: NCT01929824
Study type: Observational
Location: Mayo Clinic, Rochester MN
Learn more

Natural History and Genetics of Food Allergy and Related Conditions

Ages: 2-99
Study Reference: NCT02504853
Study Type: Observational
Location: Maryland
Learn more

Pilot Study for Imaging of the Esophagus Using an OFDI Capsule

Ages: 16+
Study Reference: NCT02204150
Study type: Interventional
Location: Boston, MA
Learn more

Pilot Study to Image the Esophagus Using Spectrally Encoded Confocal Microscopy (SECM)

Ages: 14+
Study Reference: NCT02202590
Study type: Interventional
Location: Boston, MA
Learn more

Protocol for Food Antigen Staining in Esophageal Mucosa in Patients With Eosinophilic Esophagitis

Ages: 18-80
Study Reference: NCT02434705 
Study type: Interventional
Location: Mayo Clinic, Rochester, MI
Learn more

 


Eosinophilic Fasciitis (EF)

Coordination of Rare Diseases at Sanford

Ages: not specified
Study Reference: NCT01793168
Study type: Observational
Location: Sioux Falls, SD
Learn more


Eosinophilic Gastroenteritis (EGE)

Benralizumab for Eosinophilic Gastritis (ANTI-IL5RA)

Ages: 12-60
Study Reference: NCT03473977
Study type: Interventional
Location: Children’s Hospital Medical Center, Cincinnati

Learn more

       Patient brochure with study information

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

Ages: consent obtained for ages 11+
Study Reference: NCT00267501
Study type: Observational
Location: Cincinnati, OH
Learn more

 

A Study of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis (ENIGMA) 

Estimated start: April 2018
Ages: 18-80
Study Reference: NCT0349571
Study type: Interventional
Location: Multiple US Sites

Learn more


Eosinophilic Gastritis (EG)

 

Benralizumab for Eosinophilic Gastritis (ANTI-IL5RA)

Ages: 12-60
Study Reference: NCT03473977
Study type: Interventional
Location: Children’s Hospital Medical Center, Cincinnati

Learn more

        Patient brochure with study information

A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EG) and Colitis (EC)

Ages: 3-65
Study Reference: NCT02523118
Study type: Observational
Location: Multiple
Learn more

 

A Study of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis (ENIGMA) 

Estimated start: April 2018
Ages: 18-80
Study Reference: NCT0349571
Study type: Interventional
Location: Multiple US Sites

Learn more


Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)

Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes

Ages: 0-20
Study Reference: NCT02006134
Study type: Observational
Location: Multiple, including international
Learn more

High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet’s Disease, and Sjogren’s Syndrome

Ages: 16-60
Study Reference: NCT00278512
Study type: Interventional
Location: Chicago, IL
Learn more

Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)

Ages: any age
Study Reference: NCT00315380
Study type: Observational
Location: Multiple, including Canada
Learn more

Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis)

Ages: 18+
Study Reference: NCT01862068
Study Type: Observational
Location: France
Learn more

Vasculitis Pregnancy Registry

Ages: 18-50 Female
Study Reference: NCT02593565
Study Type:  Observational/Patient Registry
Location:  Online Registry
Learn more

VCRC Genetic Repository One-Time DNA Protocol

Ages: 7+
Study Reference: NCT01241305
Study type: Observational
Location: Multiple, including Canada
Learn more


HES (Hypereosinophilic Syndrome)

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

Ages: 12+
Study Reference: NCT03306043
Study type: Interventional
Location: Multiple,  international
Learn more

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Ages: 12+
Study Reference: NCT02836496
Study type: Interventional
Location: Multiple, including international sites
Learn more

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

Ages: 18-65
Study Reference: NCT02130882
Study type: Interventional
Location: Bethesda, MD
Learn more

A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects With Hypereosinophilic Syndrome

Ages: 12+
Study Reference: NCT00244686
Study type: Interventional
Location: Multiple, including international sites
Learn more

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

Ages: any age
Study Reference: NCT00091871
Study type: Observational
Location: Bethesda, MD
Learn more

Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes

Ages: 7+
Study Reference: NCT01524536
Study type: Interventional
Location: Bethesda, MD
Learn more

Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients With Myeloproliferative and/or Steroid-Refractory Hypereosinophilic Syndrome

Ages: 2+
Study Reference: NCT00044304
Study type: Interventional
Location: Bethesda, MD
Learn more

SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

Ages: 18+
Study Reference: NCT02268253
Study Type: Interventional
Location: Multiple US/Canada
Learn more 


Vasculitis

One-Time DNA Study for Vasculitis

Study Reference: NCT01241305
Location: Please view the link below for the complete list of locations.
Learn more

Vasculitis Pregnancy Registry

Ages: 18-50 Female
Study Reference: NCT02593565
Study Type:  Observational/Patient Registry
Location:  Online Registry
Learn more